Tag: GlobeNewswire

Sezzle, a leader in BNPL, sees engagement surge with its in-app financial education tool as users build real-world money skills and put them into practice

Minneapolis, MN, Oct. 06, 2026 (GLOBE NEWSWIRE) — Sezzle Inc. (NASDAQ:SEZL) (Sezzle or Company) // – Sezzle, the digital financial platform specializing in Buy Now, Pay Later, today announced that Money IQ, its in-app financial literacy platform powered by Zogo, has surpassed 2 million completed modules among more than 338,000 users.

A majority of Americans say they feel unprepared to navigate shifting financial challenges, from rising costs to economic uncertainty. Sezzle saw that gap and built Money IQ— core lessons are free to download and use, with no subscription required. The platform creates a pipeline for users’ financial journeys right inside its app: learn a skill, like budgeting or building credit, then put it into practice in the real world — all while earning Sezzle Points for every completed lesson along the way — so the more users learn, the more they earn. Users can then redeem points for Sezzle Spend or gift cards to Amazon, DoorDash, Instacart, and more.

That design is already showing results. As of October 2026, Money IQ users have logged over 68,100 hours of learning. That engagement is translating into real behavior change: according to Sezzle’s March 2026 Money IQ user survey, 91% of surveyed users report that Money IQ has been helpful in making financial decisions, and 90% feel more confident managing their finances since using the platform— with opening a bank account, saving money, and building credit among the most-completed lessons.

“We’re building an all-in-one app for the everyday American’s financial journey, start to finish. Our investment in Money IQ and the rewards surrounding it are an important part of helping users learn how to build and manage credit and save money, then put those same skills to use in their daily lives. That’s the full pipeline we’re building: learn it, then live it,” said Charlie Youakim, CEO and Co-Founder of Sezzle.

“Sezzle is raising the bar for what customers should expect from a financial platform. They were the first partner we worked with to build their own rewards program into the app around financial education, and Money IQ’s growing engagement speaks to that commitment. We’re proud to build alongside a partner that’s making financial knowledge a meaningful part of the customer experience,” said Ben Brooks, President of Zogo.

Money IQ is one piece of Sezzle’s bigger vision: a one-stop app that meets the everyday American wherever they are in their financial journey and gives them the tools to move forward responsibly. 

To learn more, visit sezzle.com and download the Sezzle app.

About Sezzle Inc.

Sezzle is a forward-thinking fintech company committed to financially empowering the next generation. Designed to support users throughout every stage of their financial journey, Sezzle’s all-in-one app enables users to shop, earn, and learn in a seamless experience. By offering point-of-sale financing and digital payment services, Sezzle enhances purchasing power while connecting millions of consumers with its global network of merchants. Centered on transparency, inclusivity, and ease of use, Sezzle empowers consumers to manage spending responsibly and build lasting financial independence.

For additional assets and news on Sezzle please visit https://sezzle.com/news/

Follow Sezzle on social media: LinkedIn | Instagram | X 

Sezzle Media Contact:

Erin Foran

Tel: (651) 403-2184

Email: erin.foran@sezzle.com

About Zogo

Zogo is a gamified financial education platform that partners with financial institutions to empower their audience through our reward based learning. While Zogo users see greater outcomes in their overall financial health and wealth journey, our partner institutions see real growth in return, like account openings, on-time payments, and more. 

To learn more about Zogo please visit https://zogo.com/ 

Follow Zogo on social media: LinkedIn | Instagram 

CONTACT: Erin Foran
Sezzle
6514032184
erin.foran@sezzle.com

Geneva, Switzerland, Oct. 06, 2026 (GLOBE NEWSWIRE) —

Investment to support next-generation satellites and integration of SEALSQ’s post-quantum security technologies across space and ground infrastructure

SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that it led a $10 million private investment in public equity (PIPE) in WISeSat.Space Holdings Corp. (Nasdaq: SAIQ) (“WISeSat.Space”), a space technology company. The investment closed on October 1, 2026. WISeSat.Space and SEALSQ are subsidiaries of WISeQey Corp. (formerly known as WISeKey International Holding AG, “WISeQey”) (Nasdaq/SIX: WQEY), a global quantum cybersecurity and space IoT company.

The PIPE Investment closed on October 1, 2026, concurrently with the closing of the Business Combination.  The purchase price per share, equal to the redemption price, was $10.79 per share.  The Subscription Agreement includes a price-protection mechanism that may result in the issuance of additional WISeSat Ordinary Shares to SEALSQ under certain conditions if the volume-weighted average price of WISeSat Ordinary Shares for the 10 consecutive trading days ending on the 60th calendar day after Closing is below the purchase price, subject to a maximum issuance of an additional 1,073,216 shares. SEALSQ is also subject to customary lock-up restrictions under the Subscription Agreement.

The investment provides WISeSat.Space with additional equity capital as it advances its space cybersecurity strategy, including the planned expansion of its satellite infrastructure, and the integration of post-quantum cryptography (PQC) security technologies into its satellites, ground and user-segment architectures.

WISeSat.Space is engaged in the development of a new generation of WISeSat.Space satellites, intended to support trusted communications, digital identity, and data exchange through space-based infrastructure. The planned architecture is intended to integrate advanced cybersecurity capabilities with satellite communications, creating a foundation for trusted and resilient communications across space and ground infrastructure.

A key focus of the program is expected to be the development of quantum-resilient secure communications capabilities, designed to address emerging cybersecurity threats associated with the future evolution of quantum computing. By incorporating post-quantum security into the satellite communications architecture, WISeSat aims to strengthen device authentication, data integrity, and secure communications across space and ground infrastructure.

The collaboration with SEALSQ is also expected to support the development of a broader trusted space infrastructure, under which WISeSat.Space would provide satellite capacity and related space and ground infrastructure, while SEALSQ would use that capacity to support the development and delivery of planned quantum and post-quantum services using its secure semiconductor, cryptographic and trusted identity technologies.

Carlos Moreira, CEO of SEALSQ, WISeSat.Space and WISeQey noted, “This investment brings together two companies within the WISeQey group around a shared goal: making space infrastructure secure against both current and future cyber threats. For WISeSat.Space, it provides capital to advance our next generation of satellites and to build post-quantum security into our space, ground and user segments. For SEALSQ, it opens a path to deliver quantum and post-quantum services using WISeSat.Space’s satellite capacity. Together, secure semiconductors, cryptography and satellite connectivity have the potential to help set new standards for trust and security across the emerging space economy.”

John O’Hara, CFO of SEALSQ, added, “This investment supports SEALSQ’s strategy to extend the application of our secure semiconductor, cryptographic and trusted identity technologies into space-based communications. By supporting the development of WISeSat.Space’s infrastructure, we aim to create a foundation for delivering post-quantum security services across satellite and ground networks. Our focus is on translating this collaboration into commercial opportunities that support long-term value for SEALSQ shareholders.”

The new satellite program is expected to contribute to WISeSat.Space’s broader vision of bringing trust and sovereignty to space transactions, enabling secure interactions among independently operated space and terrestrial systems while strengthening the protection of critical digital assets.

Related Party Transactions
WISeQey, WISeSat.Space, and SEALSQ are affiliated companies part of the same corporate family. Carlos Moreira serves as Chief Executive Officer of each company. Accordingly, the PIPE investment and the planned collaboration between WISeSat.Space and SEALSQ described in this press release are related party transactions.

About WISeQey

WISeQey Corp. (“WISeQey”), is a British Virgin Islands holding company focused on post quantum cybersecurity, digital identity, space technology and the Internet of Things (IoT). Its operating subsidiaries and technology platforms address distinct parts of this portfolio:

1. SEALSQ Corp (Nasdaq: LAES) develops secure semiconductors, public key infrastructure (PKI) and post-quantum security products.
2. WISeSat.Space (Nasdaq: SAIQ) develops space technology and secure satellite communications, particularly for IoT applications.
3. WISeID provides digital identity, authentication, secure access and digital signing for individuals, enterprises and connected devices.
4. WISe.ART Corp operates the WISe.ART marketplace, which uses blockchain technology to support trusted digital asset and NFT transactions.
5. SEALCOIN AG develops decentralized physical infrastructure network (DePIN) technology and the SEALCOIN platform.

Each subsidiary contributes to WISeQey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeQey platform. WISeQey secures digital identity ecosystems for individuals and objects using blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeQey plays a vital role in securing the Internet of Everything. Trusted by the OISTE/WISeQey cryptographic Root of Trust, WISeQey provides secure authentication and identification for IoT, blockchain, and AI applications. The WISeQey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeQey’s strategic direction and its subsidiary companies, please visit www.wisekey.com.

About WISeSat

WISeSat is a space technology company focused on secure satellite communications for Internet of Things applications. Its approach combines satellite infrastructure with cybersecurity and digital identity technologies to support trusted communications between connected devices and ground-based systems.

About SEALSQ:
SEALSQ is a leading innovator in Post-Quantum Technology hardware and software solutions. Our technology seamlessly integrates Semiconductors, PKI (Public Key Infrastructure), and Provisioning Services, with a strategic emphasis on developing state-of-the-art Quantum Resistant Cryptography and Semiconductors designed to address the urgent security challenges posed by quantum computing. As quantum computers advance, traditional cryptographic methods like RSA and Elliptic Curve Cryptography (ECC) are increasingly vulnerable.

SEALSQ is pioneering the development of Post-Quantum Semiconductors that provide robust, future-proof protection for sensitive data across a wide range of applications, including Multi-Factor Authentication tokens, Smart Energy, Medical and Healthcare Systems, Defense, IT Network Infrastructure, Automotive, and Industrial Automation and Control Systems. By embedding Post-Quantum Cryptography into our semiconductor solutions, SEALSQ ensures that organizations stay protected against quantum threats. Our products are engineered to safeguard critical systems, enhancing resilience and security across diverse industries.

For more information on our Post-Quantum Semiconductors and security solutions, please visit www.sealsq.com.

Forward-Looking Statements
This communication expressly or implicitly contains certain forward-looking statements concerning SEALSQ Corp and its businesses. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, events or developments that we expect or anticipate will occur in the future, as well as any other statements which are not historical facts. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include SEALSQ’s ability to continue beneficial transactions with material parties, including a limited number of significant customers; market demand and semiconductor industry conditions; and the risks discussed in SEALSQ’s filings with the SEC. Risks and uncertainties are further described in reports filed by SEALSQ with the SEC.

SEALSQ Corp is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SEALSQ Corp. Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 info@sealsq.com

SEALSQ Investor Relations (US) The Equity Group Inc. Lena Cati Tel: +1 212 836-9611 Lena.cati@theequitygroup.com

The Board of Directors has convened the General Meeting to approve a 20-for-1 share consolidation to ensure continued compliance with Nasdaq listing requirements

LONDON, Oct. 06, 2026 (GLOBE NEWSWIRE) — RedCloud Holdings plc (Nasdaq: RCT) (“RedCloud” or the “Company”), which is building the AI prediction infrastructure for global FMCG trade, today announced that its Board of Directors has convened a General Meeting of shareholders (the “General Meeting”) to be held on Friday, October 30, 2026 at 10:00AM ET / 14:00 GMT for shareholders of record as of the close of business on September 25, 2026.

At the General Meeting, the Company will seek shareholder approval to effect a share consolidation pursuant to which every 20 existing ordinary shares of £0.002 each in the capital of the Company will be consolidated into one new ordinary share of £0.04 in nominal value each (the “Consolidated Ordinary Shares”). Where such consolidation results in any shareholder being entitled to a fraction of a new Consolidated Ordinary Share, no shareholder will be entitled to receive a fraction of a Consolidated Ordinary Share, and such fractions will be aggregated into whole shares and the directors of the Company are authorized to sell, or appoint another person to sell, the aggregated whole shares for the best price reasonably obtainable.  The net proceeds of such sale, after deduction of the expenses of the sale, will be distributed in due proportion among the members who would otherwise be entitled to the fractions. If approved by shareholders, the share consolidation is expected to be effective on or about November 13, 2026.

The share consolidation will not change the proportionate ownership interest of any shareholder, and should enable the Company to comply with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Full details of the proposals to be presented to the Company’s shareholders, which include a necessary amendment to the Company’s articles of association, are set out in the Notice of General Meeting and accompanying proxy materials that were distributed to shareholders on October 5, 2026. The Company’s directors and named executive officers that hold shares, along with the Company’s largest shareholder, have committed to voting in favor of the transaction.

Receipt of Nasdaq Minimum Bid Price Letter

As previously disclosed, on April 15, 2026 the Company received formal notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based on the closing bid price of the Company’s ordinary shares for the then-preceeding 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1 per share (the “Nasdaq Minimum Bid Price Rule”). Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 180 calendar days, or until October 12, 2026, in which to regain compliance with the minimum bid price requirement.

Separately, the Company received formal notification from Nasdaq on August 10, 2026 that the Company was not in compliance with the minimum market value of listed securities set forth in Nasdaq’s rules for continued listing on the Nasdaq Capital Market (the “Second Deficiency Notice”). Nasdaq Listing Rule 5550(b)(2) requires primary securities listed on the Nasdaq Capital Market to maintain a minimum market value of listed securities of $35,000,000 (the “MVLS Requirement”), and Listing Rule 5810(c)(3)(C) provides that a failure to meet the MVLS Requirement exists if a deficiency under Rule 5550(b)(2) continues for a period of 30 consecutive business days. Based on the market value of the Company’s listed securities for a period of greater than 30 consecutive business days prior to August 6, 2026, the Company was not in compliance with the MVLS Requirement.

Due to the Second Deficiency Notice, the Company does not expect to be eligible for a second 180-day compliance period related to the Nasdaq Minimum Bid Price Rule. Accordingly, the Company expects it will receive a delisting determination from Nasdaq on or about October 12, 2026. Under current rules, the Company will be entitled to appeal that determination by filing a request for an oral hearing before the Nasdaq Hearings Panel (the “Hearings Panel”) pursuant to Nasdaq Listing Rule 5815, and the Company intends to file such request. Per Rule 5815(a)(1)(B), this request will stay the suspension of trading or delisting of the Company’s securities pending the hearing and the Hearings Panel’s decision. In the meantime, the Company’s ordinary shares will continue to trade in the normal manner on the Nasdaq Capital Market under the symbol RCT. Per Listing Rule 5815(a)(5), the Company will submit to the Hearings Panel a written plan of compliance, including a commitment to effect a reverse stock split, and request that the Hearings Panel grant an exception to the listing standards for a limited time period, as permitted by Rule 5815(c)(1)(A). Depending on the timing of the hearing before the Hearings Panel, the share consolidation may already be effective.

A share consolidation combines a number of existing shares into a smaller number of shares of a proportionally higher nominal value. The total value of the Company and each shareholder’s proportionate ownership interest remain unchanged, only the number of shares in issue and the price per share are affected. A share consolidation is a commonly used mechanism to increase the market price per share and restore compliance with the Nasdaq minimum bid price requirement, as by reducing the number of shares in issue the price per share increases proportionately. The new Consolidated Ordinary Shares will carry the same rights and be subject to the same restrictions as the Company’s new articles of association.

If approved by shareholders, we anticipate the Company will evidence a closing bid price of at least $1 per share for a minimum of 10 consecutive business days following the effective date of the share consolidation.  If the Company fails to regain compliance with the Nasdaq continued listing standards, Nasdaq will provide notice that the Company’s ordinary shares will be subject to delisting.

About RedCloud

RedCloud Holdings plc (Nasdaq: RCT) builds AI infrastructure for the prediction of FMCG trade. More than $8.4 billion of FMCG transactions have passed through its infrastructure between early 2023 and June 2026, across more than 100,000 customers and 6,700 brands. RedCloud uses this proprietary transaction data to develop RAID (Real-time AI for Distribution), its prediction model for distribution, and deploys its infrastructure and associated products (“RedAI”) either directly or through joint ventures with partners who fund and operate local markets.

RedCloud is a British company registered in London. Justin Floyd is its Founder and Chief Executive Officer. For more information, please visit www.redcloudtechnology.com and connect on LinkedIn.

Forward-Looking Statements

The information in this press release may include forward-looking statements within the meaning of the federal securities laws. These statements include, without limitation, statements regarding the expected general meeting of shareholders. Words such as “expect,” “project,” “estimate,” “believe,” “anticipate,” “intend,” “plan,” “seek,” “forecast,” “target,” “predict,” “may,” “should,” “would,” “could,” and “will,” the negative of these terms and similar expressions are intended to identify forward-looking statements. Forward-looking statements are based on management’s current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, including, but not limited to, the Company’s intention to request a hearing before the Hearings Panel, the outcome of the General Meeting, the completion of the share consolidation, and the closing bid price for the 10-day period following such share consolidation. As a result, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements described in “Cautionary Note Regarding Forward-Looking Statements,” “Item 3. Key Information – D. Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in RedCloud’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission, as well as the Company’s periodic reports and other filings with the Securities and Exchange Commission. RedCloud undertakes no obligation to update or revise these forward-looking statements except as required by law.

Contacts

Investor Relations
investor.relations@redcloudtechnology.com 

Media Relations
media@redcloudtechnology.com 

• The Q3 2026 Pulse Survey finds 55% of U.S. voters say seeing a social media post has informed (28%) or changed (27%) their opinion on who to vote for
• 50% of Americans follow at least one politician on social, and 33% say seeing their posts directly makes them seem more approachable
• At the same time, 80% are worried about encountering AI-generated deepfakes of political candidates during voting season

CHICAGO, Oct. 06, 2026 (GLOBE NEWSWIRE) — Ahead of the 2026 midterms, new research reveals social media has become an increasingly influential factor in elections, particularly for younger voters. According to Sprout Social’s Q3 2026 Pulse Survey, 55% of Americans say a social media post has informed or changed their opinion on who to vote for. Among Gen Z, that number rises to 79%, and nearly half (48%) say a social post has changed their opinion outright.

That influence reflects where younger audiences now get their information. While TV is still the top source for midterm election news overall, social media ranks first among Gen Z and Millennials. Its role will only grow as Election Day approaches, with over 1 in 5 Gen Z and Millennial users planning to use social media more to follow election news ahead of the midterms. In addition, Gen Z is nearly twice as likely as the general population to rely on creators and influencers they follow for election information.

The survey also shows how social media actively shapes candidate perception. One-third of Americans — and 42% of Millennials — say politicians seem more approachable when they post about their policies. With half of respondents and 70% of Gen Z following at least one politician on social media, direct social engagement can significantly improve how candidates are perceived.

However, social’s growing influence comes with a significant trust challenge in the AI era. Four in five Americans worry about encountering candidate deepfakes during voting season, with 40% extremely concerned. And the impact isn’t limited to a single post: finding out a political ad is AI-generated makes 35% of people skeptical of all political ads, and 29% say they would trust the politician behind it less.

The findings also offer a clear signal for brands navigating the midterms: maintain business as usual. Americans are twice as likely to want companies to keep posting regular content while steering clear of politics (23%) as they are to want them to pause until the election passes (11%). That preference holds across generations and the political spectrum, underscoring that audiences still value consistency and authenticity from the brands they follow, even during a political news cycle.

For more insights, from the election season to the holiday shopping season, access the full Q3 2026 Pulse Survey here.

About the data
This consumer survey was conducted online by Glimpse, a global market research firm, on behalf of Sprout Social. Participants included 2,286 social media users across the U.S., U.K., and Australia, with midterm-specific questions asked of 1,026 U.S. respondents. The survey was conducted from August 11, 2026, to August 18, 2026.

About Sprout Social
Sprout Social is a leading AI-powered Social Intelligence platform, built on the belief that All Business is Social℠. Powered by Trellis, Sprout’s proprietary AI agent, the platform transforms real-time social media signals into actionable insights that drive business forward. Consistently recognized as a top software by G2, Sprout enables brands to deliver smarter, faster business impact through a suite of solutions including comprehensive publishing and engagement, customer care, influencer marketing, advocacy and predictive media intelligence. Sprout’s software operates across all major social networks and digital platforms. For more information about Sprout Social (NASDAQ: SPT), visit sproutsocial.com.

Social Media Profiles
www.x.com/SproutSocial
www.x.com/SproutSocialIR
www.facebook.com/SproutSocialInc
www.linkedin.com/company/sprout-social-inc-/
www.instagram.com/sproutsocial

Media Contact
Abigail Hart
Email: pr@sproutsocial.com
Phone: (860) 309-4550

Investors:

Lexi Johnson

Twitter: @SproutSocialIR

Email: investors@sproutsocial.com

Phone: (312) 528-9166

Segment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Company’s path forward following the FDA approval of LYTENAVA™

Access the segment here

ISELIN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it participated in a Virtual Investor “What This Means” segment featuring Kevin Lundquist, the Company’s recently appointed Chief Financial Officer

In the discussion, Mr. Lundquist shares his perspective on joining Outlook Therapeutics at such a pivotal time for the Company following the U.S. Food and Drug Administration approval of LYTENAVA, the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD). He also discusses the opportunity ahead as Outlook Therapeutics advances toward the commercial launch of LYTENAVA in the United States.

“Joining Outlook Therapeutics at this point in the Company’s evolution was a compelling opportunity,” said Kevin Lundquist, Chief Financial Officer of Outlook Therapeutics. “With FDA approval of LYTENAVA, we have entered an important new chapter as we transition into a commercial-stage company. I look forward to helping execute on our strategy, supporting the successful launch of LYTENAVA, and working to build long-term value for shareholders.”

The Virtual Investor “What This Means” segment is available to watch here.

About LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)

LYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the United States for the treatment of wet AMD. In the United States, LYTENAVA (bevacizumab-vikg) is the only ophthalmic formulation approved by the FDA. LYTENAVA (bevacizumab gamma) is also the subject of a centralized Marketing Authorization granted by the European Commission in the EU and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of adults with wet AMD. In certain European Union Member States, LYTENAVA must receive pricing and reimbursement approval before it can be sold.

Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized IgG1 monoclonal antibody specific to human vascular endothelial growth factor (VEGF). Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. LYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses endothelial cell proliferation, neovascularization, and vascular permeability. Inhibition of such activity targets a pathophysiologic process that contributes to vision loss.

Important Safety Information and Indication

LYTENAVA (bevacizumab-vikg) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).

Contraindications

LYTENAVA is contraindicated in patients with ocular or periocular infections, in patients with active intraocular inflammation, and in patients with a known hypersensitivity to bevacizumab products or any of the ingredients in LYTENAVA. Hypersensitivity reactions may manifest as severe intraocular inflammation.

Warnings and Precautions

Intravitreal injections have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering LYTENAVA. In addition, patients should be monitored following the injection to permit early treatment should an infection occur.

Increases in intraocular pressure have been noted post-injection (up to 60 minutes) while being treated with LYTENAVA. Monitor intraocular pressure prior to and following intravitreal injection with LYTENAVA and manage appropriately.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LYTENAVA clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Adverse Reactions

The most common adverse reactions (≥1%) reported in patients receiving LYTENAVA were conjunctival hemorrhage (4%), eye pain (2%), and vitreous floaters (2%). These are not all the possible side effects of LYTENAVA.

You are encouraged to report side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Outlook Therapeutics at 1-833-999-OTLK (6855).

Please see the full U.S. Prescribing Information for LYTENAVA here.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg (U.S.), bevacizumab gamma (E.U.)). LYTENAVA is the only ophthalmic formulation of bevacizumab to receive U.S. FDA approval and European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.

Forward-Looking Statements

This press release contains statements that may or are considered “forward-looking statements”. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “may,” “on track,” “plan,” “potential,” “target,” “will,” or “would”, the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, express or implied discussions regarding the Company’s planned launch of LYTENAVA in the United States and other jurisdictions and the timing thereof; expectations concerning potential revenue generation from sales of LYTENAVA; expectations surrounding market adoption of LYTENAVA; expectations regarding the potential impact of LYTENAVA in the retina community; Outlook Therapeutics’ development or future revenue plans for LYTENAVA generally; and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Current Report on Form 8-K filed with the SEC on August 12, 2026 and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and future reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, tariffs, and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com

CEO Jan Goetgeluk to Meet with Institutional Investors Following 3X Omni One Order Growth and Expanding U.S. Government Adoption

AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — Virtuix Holdings Inc. (NASDAQ: VTIX), a leading developer of AI-driven, full-body simulation systems, today announced that Founder, Chief Executive Officer, and Chairman Jan Goetgeluk will highlight the Company’s recent consumer growth and expanding defense sales at the 2026 Maxim Growth Summit, being held October 13 and 14, 2026 at the Hard Rock Hotel New York.

Mr Goetgeluk’s meetings with institutional investors follow a series of recent commercial milestones across Virtuix’s consumer, defense, enterprise, and healthcare markets. Omni One consumer orders have been running at approximately 3X the prior-year level following the Company’s June launch of Omni One for Quest in collaboration with Meta. Virtuix has also completed its U.S. Air Force AFWERX Phase I SBIR program, expanded its work in counter-UAS and military training, and sold Omni One systems to the U.S. Department of Veterans Affairs and the U.S. Navy’s Morale, Welfare and Recreation (“MWR”) Program.

In enterprise and robotics, Omni One is being used in applications including humanoid robot teleoperation, with Tesla placing repeat Omni One Enterprise orders for its Optimus program and Figure AI also purchasing an Omni One Enterprise system.

Virtuix’s healthcare initiatives now include deployments and evaluation across the U.S. Department of Veterans Affairs, autism therapy for children, and rehabilitation applications, further extending the Omni technology platform beyond its original consumer gaming market.

“Virtuix is increasingly becoming much more than a consumer VR company,” said Jan Goetgeluk, Founder, Chairman and CEO. “The same full-body simulation platform is now gaining adoption across consumer entertainment, defense training, humanoid robotics, and healthcare. With consumer orders growing, government programs advancing, and enterprise customers placing repeat orders, I look forward to discussing our growth strategy and the opportunities ahead with institutional investors at the Maxim Growth Summit.”

Mr Goetgeluk is expected to discuss the commercial trajectory of the Omni platform, its adoption across consumer, defense, humanoid robotics, and healthcare markets, and the Company’s organic and strategic growth opportunities.

Maxim Growth Summit 2026
Dates: October 13 and 14, 2026
Location: Hard Rock Hotel New York, 159 West 48th Street, New York, NY 10036
Conference Website: Here
Format: One-on-One Investor Meetings
Attendees: Jan Goetgeluk, Founder, Chief Executive Officer, and Chairman

To schedule a one-on-one meeting with management at the Maxim Growth Summit 2026, please contact your Maxim Group representative. You may also email your request to VTIX@mzgroup.us or call Chris Tyson at (949) 491-8235.

About Virtuix

Virtuix Holdings Inc. (NASDAQ: VTIX) is a developer of AI-driven, full-body immersive simulation systems and the creator of the “Omni” omni-directional treadmill. Virtuix’s technology lets users physically move through virtual and AI-generated environments. The Company’s products are deployed across consumer entertainment, defense training and simulation, robotics, healthcare, research, and enterprise applications involving organizations including Meta, NASA, Tesla, KBR, and Sirica Therapeutics. The Company’s growing federal and defense footprint includes programs, deployments, and research initiatives involving the U.S. Army, Marine Corps, Navy, and Air Force.

Virtuix continues to expand the Omni brand from immersive entertainment into a broader, full-body simulation technology platform serving multiple commercial and government markets. For more information, visit virtuix.com or the Company’s new Investor Relations website at invest.virtuix.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “could,” “would,” “potential” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding the Company’s sales and expansion plans, plans to pursue strategic acquisitions, potential impacts on future revenues or shareholder value, and the Company’s position in the defense training market. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the Company’s ability to identify, negotiate, and complete acquisitions on favorable terms or at all; the ability to successfully integrate any acquired business; risks related to government contracting, including contract cancellations, modifications, or funding changes; the uncertainties related to market conditions; and other factors discussed in the “Risk Factors” section of the Company’s registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Visit Us on Social Media:
LinkedIn
Instagram
Facebook
YouTube
TikTok
X

Company Contact
Lauren Premo
Virtuix Inc.
press@virtuix.com

Investor Relations Contact
Chris Tyson
MZ Group
Direct: 949-491-8235
VTIX@mzgroup.us

Company and development partner Kopin have executed non-disclosure agreements with leading semiconductor and data center companies; technical discussions are underway ahead of hardware demonstrations planned for early 2027

NEW YORK, NY, Oct. 06, 2026 (GLOBE NEWSWIRE) — Fabric.AI (Nasdaq: FABC) (“Fabric.AI” or the “Company”), an AI infrastructure company developing a suite of fabless semiconductor technologies for next-generation AI factories, today announced that it has engaged Kearney, the global technology-focused management consulting firm, to apply its world-class infrastructure and supply chain expertise to accelerate and enhance the commercialization strategy for its Neural I/o™ MicroLED-based optical interconnect platform.

James Altucher, independent strategic advisor to Fabric.AI, commented, “Neural I/o™ addresses the two constraints that will define the next generation of AI data centers — how much data you can move, and what it costs in power to move it. We are already in confidential discussions with companies operating at the scale where those constraints bite hardest. Kearney’s role is to help us turn those conversations into commercial relationships, and to reach the semiconductor and infrastructure partners best positioned to bring this technology to market at scale. We anticipate active sales discussions beginning shortly after we demonstrate working hardware early next year.”

The engagement builds on confidential work already underway. Together with its development partner Kopin Corporation (Nasdaq: KOPN), Fabric.AI has executed non-disclosure agreements with several leading semiconductor and data center technology companies, and technical discussions with those counterparties are ongoing. Kearney’s mandate is to help Fabric.AI convert that early engagement into a structured commercial pipeline — sharpening product positioning, identifying and prioritizing target customers and channel partners, and preparing the Company for active sales discussions expected to begin following its planned hardware demonstrations in early 2027.

About Kearney

For 100 years, Kearney has been a leading management consulting firm and trusted partner to three-quarters of the Fortune Global 500 and governments around the world. With a presence across more than 40 countries, our people make us who we are. We work impact first, tackling your toughest challenges with original thinking and a commitment to making change happen together. By your side, we deliver—value, results, impact. Learn more at www.kearney.com.

About Fabric.AI

Fabric.AI (Nasdaq: FABC) is an AI infrastructure company developing a suite of fabless semiconductor technologies for next-generation AI factories, including its Neural I/o™ MicroLED-based optical interconnect platform.

About Kopin Corporation

Kopin Corporation (Nasdaq: KOPN) is a leading developer and provider of innovative display and application-specific optical solutions for defense, AI infrastructure, enterprise, professional and consumer products. Kopin’s portfolio includes microdisplays, display modules, eyepieces and projection assemblies, and vehicle- and head-mounted display systems built on Kopin’s liquid crystal, MicroLED and OLED display technologies, along with a range of optics and low-power custom silicon. Building on its patented bi-directional NeuralDisplay™ architecture, Kopin is also developing Neural I/o optical interconnects that use programmable MicroLED pixels as ultra-high-speed, low-power optical transceivers for AI data centers. For more information, please visit Kopin’s website at www.kopin.com.

Follow Kopin on LinkedIn, X and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the expected timing, demonstration and capabilities of the Neural I/o™ platform, the anticipated benefits and scope of the Company’s engagement with Kearney, and the progress, timing or outcome of confidential discussions with potential partners and customers. The existence of a non-disclosure agreement or of ongoing technical discussions does not constitute a commercial commitment, and there can be no assurance that any such discussion will result in a definitive agreement, a design win, or revenue. These statements are based on current expectations and are subject to risks and uncertainties — including development, integration and manufacturing risks — that could cause actual results to differ materially. Market and industry data are derived from third-party sources believed to be reliable but have not been independently verified by the Company. A discussion of these and other factors with respect to the Company is set forth in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

IR Contact:
CORE IR
212-644-0924
ir@fabric-ai.co 

Media Contact:
Fabric.AI
press@fabric-ai.co
www.fabricai.com 

Hong Kong, Oct. 06, 2026 (GLOBE NEWSWIRE) — Magic Empire Global Limited (NASDAQ: MEGL) (“MEGL” or the “Company”) today announced a new strategic initiative to expand into international commodity trading and supply chain finance, building on its established financial services platform in Hong Kong. Going forward, the Company intends to develop its business around two core pillars: commodity trading, focusing on mineral and energy resources, and financial services, centered on supply chain finance.

The Company has established a wholly-owned subsidiary in Hong Kong, Lunar Haste International Trading Limited, through which it is developing an integrated business comprising two complementary segments:

Commodity Trading: cross-border trading of timber, mineral and coal products, initially focusing on hardwood logs and sawn timber, iron ore, thermal coal and metallurgical coal, supplied to buyers in the United States, Europe and the Asia-Pacific region.

Supply Chain Finance: financing solutions for upstream suppliers and downstream buyers in the commodity sector, which may include pre-export financing, inventory and warehouse receipt financing, receivables financing, and letter of credit facilitation and related arrangements. Such financing solutions will be provided, where required, through licensed entities or in cooperation with licensed financial institutions, subject to applicable laws and regulations.

The Company has established a mature partnership network and supply chain resources across North America, Europe and Africa, including relationships with producers, mine operators, timber mills and end buyers. These resources are expected to provide the Company with stable access to supply and diversified sourcing channels from the outset of its trading operations.

The expansion is further anchored by the extensive industry experience of the Company’s management team, which has more than 30 years of experience in commodity trading and has held key management roles at a number of multinational commodity, mineral and energy trading companies.

The Company believes that combining physical trading with supply chain finance creates a mutually reinforcing model. Trading activities provide direct visibility into cargo flows, counterparty performance and collateral quality, which supports disciplined credit decisions, while financing capabilities strengthen relationships with suppliers and buyers and enhance the Company’s trading competitiveness.

“Our management team has spent more than 30 years building relationships across global commodity supply chains, and we have established a mature partnership network spanning North America, Europe and Africa,” said Mei Wang, CFO of MEGL. “By pairing that industry expertise with MEGL’s financial services capabilities, we can offer our partners both reliable trading channels and tailored financing. Commodity trading and supply chain finance will be the two pillars of MEGL’s growth going forward.”
The Company has completed its first commodity trading transaction through Lunar Haste International Trading Limited in the fourth quarter of 2026.

About Magic Empire Global Limited

Magic Empire Global Limited is a Hong Kong-based company engaged in financial services, including corporate finance advisory and underwriting services, and is expanding into international commodity trading and supply chain finance.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, including those regarding the Company’s expansion into commodity trading and supply chain finance, its dual core business strategy, and anticipated benefits, are based on current expectations and are subject to risks and uncertainties, including commodity price volatility; counterparty, credit and collateral risk associated with trading and financing activities; supply chain and logistics disruptions; compliance with timber legality and responsible sourcing requirements; sanctions and export control regulations applicable to mineral, energy and coal products; environmental and climate-related regulations and policies affecting coal; licensing requirements applicable to lending and financing activities; and other risks described in the Company’s filings with the SEC. Actual results may differ materially. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Contact
International Elite Capital
Annabelle Zhang
+1 (646) 866-7928
management@iecapitalusa.com

Everest Group recognizes TTEC’s CXM capabilities across vision and strategy, scope of services, innovation and investments, and global delivery

AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — TTEC, a leading global consulting, technology, and managed services company delivering solutions at the intersection of data, AI, and customer experience (CX), today announced it has been recognized by Everest Group for the sixth consecutive year in its Customer Experience Management (CXM) Services PEAK Matrix^® Assessment for the Americas. In the 2026 assessment, TTEC was positioned as a Major Contender in the Americas, and a Major Contender and Star Performer in EMEA.

The Everest Group assessment evaluates CXM providers across Market Impact and Vision & Capability, including vision and strategy, scope of services offered, innovation and investments, and delivery footprint. TTEC received strong evaluations across all these areas and placed among the top five providers in the Americas for Vision & Capability.

“TTEC continues to be positioned as a Major Contender in Everest Group’s Customer Experience Management (CXM) Services PEAK Matrix^® Assessment 2026 – Americas, supported by its broad CXM service portfolio, diversified enterprise client base, and combination of operational and technology expertise,” said Chhandak Biswas, Vice President, Everest Group. “Alongside TTEC Digital’s CX consulting and implementation capabilities, TTEC has invested in applying AI directly to frontline performance through areas such as simulation-based learning, coaching, knowledge support, and performance management. Its ability to combine these capabilities with scaled service delivery and high-touch support enables it to address both operational improvement and customer experience transformation.”

TTEC combines CX operations, technology, consulting, and AI-enabled services

TTEC’s CXM services span customer service, technical support, sales, order fulfillment and transaction processing, talent management, knowledge management, and customer retention. AI-enabled capabilities include proprietary solutions such as TTEC ADDI for voice translation, TTEC Let Me Know for agent knowledge support, and TTEC Perform for coaching and performance management.

“Customer experience is entering a new era in which AI must work alongside people, technology, and operations to deliver meaningful business results,” said John Abou, CEO of TTEC Engage. “Our focus is on helping clients connect those capabilities to improve customer interactions, strengthen operations, and create lasting value.”

The recognition extends across TTEC’s global CXM capabilities. In Everest Group’s 2026 EMEA CXM Services PEAK Matrix^® Assessment, TTEC was recognized as both a Major Contender and Star Performer. The Star Performer designation recognizes providers that demonstrate the greatest improvement from one assessment cycle to the next across the variables evaluated.

AI and technology integration are reshaping customer experience management

Everest Group reports that enterprises are moving beyond stand-alone generative AI tools toward integrated human-AI operating models and early agentic workflows, with greater emphasis on governance, integration, adoption, and measurable returns.

TTEC combines AI and technology with CX operations through a broad ecosystem spanning cloud, CRM, CCaaS, analytics, automation, conversational AI, workforce management, and knowledge management. Its technology ecosystem includes Microsoft, AWS, Google Cloud, Salesforce, Genesys, NICE, and Cisco, among others.

The Everest Group assessment is based on its annual request for information process, interactions with CXM service providers, client reference checks, and ongoing analysis of the CXM services market. The 2026 Americas assessment features 63 CXM service providers.

Read the full assessment to learn how TTEC’s CXM capabilities, AI-enabled solutions, technology expertise, and global delivery contributed to its recognition: TTEC Recognized by Everest Group for Sixth Consecutive Year in CXM Services PEAK Matrix^® Assessment for the Americas | TTEC

About TTEC
TTEC Holdings, Inc. (NASDAQ: TTEC) is a leading global consulting, technology, and managed services company delivering solutions at the intersection of data, AI, and customer experience. Serving iconic and disruptive brands, TTEC’s outcome-based solutions span the enterprise, touch every virtual interaction channel, and improve each step of the customer journey. TTEC Digital designs, builds, and operates omnichannel contact center technology, CRM, AI, and analytics solutions. The company also delivers AI-enhanced customer engagement, customer acquisition and growth, tech support, back-office, and fraud prevention services. Founded in 1982, TTEC brings technology and humanity together to deliver differentiated customer experiences and business results. The company’s employees operate on six continents. To learn more, visit ttec.com.

Disclaimer
Licensed extracts taken from Everest Group’s PEAK Matrix^® Reports may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix^® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix^® reports are independent, and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix^® Reports. 

Media Contact
Meredith Matthews
meredith.matthews@ttec.com

COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR 2026, the annual meeting of American Society for Bone & Mineral Research being held in Boston from October 9-12, 2026. Updates include an oral presentation by Aliya Khan, M.D., of combined skeletal data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials showing normalization of bone mass and microarchitecture in clinical trial patients treated with TransCon^® PTH (palopegteriparatide) over a 5-year period.

“Our growing body of clinical trial data continues to illustrate the unique potential for our differentiated TransCon-based therapies to improve patient health and quality of life,” said Aimee Shu, M.D., Executive Vice President, Chief Medical Officer at Ascendis Pharma. “Compelling long-term data such as these help inform treatment paradigms focused on outcomes that matter most to patients, and we look forward to sharing additional results as our programs advance.”

Ascendis presentations at ASBMR 2026:

ORAL PRESENTATION
Hypoparathyroidism
Sunday, Oct. 11 Session: 11:30a.m.-12:30p.m. Presentation: 12:18 PM – 12:30 Calcium Homeostasis Disorders Ballroom A&B	ID #6080: Long-Term Effects of Palopegteriparatide on BMD and TBS in Adults With Chronic Hypoparathyroidism: Pooled Results from the PaTH Forward and PaTHway Trials Presented by Aliya Khan, M.D.
POSTERS
Hypoparathyroidism
Thursday, Oct. 8 5:30-6:30p.m. ASBMR/RBDA Pre-Meeting Symposium — Sunday, Oct. 11 2:00-3:00p.m. Poster Session II	ID #6680: Hypoparathyroidism: Understanding the Impact of Palopegteriparatide on Patients’ Health Related Quality of Life, Functioning, and Well-Being Presented by Meryl Brod, Ph.D.
Achondroplasia
Friday, Oct. 9 5:30-7:00p.m. Plenary Poster Session — Saturday, Oct. 10 2:00-3:30pm Poster Session 1	ID 6329: Improved Growth and Physical Functioning in Children with Achondroplasia Treated with Navepegritide in the ApproaCH Trial Open-Label Extension Presented by Ciara McDonnell, M.D.
Thursday, Oct. 8 5:30-6:30p.m. ASBMR/RBDA Pre-Meeting Symposium — Friday, Oct. 9 5:30-7:00p.m. Plenary Poster Session — Saturday, Oct. 10 2:00-3:30pm Poster Session I	ID 6320: Continued Improvements in Lower Extremity Alignment in Navepegritide-Treated Children With Achondroplasia: Week 104 Results from the ApproaCH Trial Presented by Leanne Ward, M.D.
Sunday, Oct. 11 2:00-3:00p.m. Late Breaking Poster Session II	Late Breaker ID 8736: Navepegritide Combined with Lonapegsomatropin for the Treatment of Children with Achondroplasia: 78-Week Results from the Phase 2 COACH Trial Presented by Ciara McDonnell, M.D.

About TransCon PTH
TransCon PTH (palopegteriparatide) is a prodrug of PTH (1-34), administered once daily, designed to provide stable levels of active PTH within the physiological range for 24 hours/day. TransCon CNP is approved as YORVIPATH^® in the United States (U.S.), European Union (EU), European Economic Area (EEA), and certain other jurisdictions as a treatment for adults with hypoparathyroidism.

About TransCon CNP
TransCon CNP (navepegritide) is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body to counteract the overactive FGFR3 signaling in achondroplasia. TransCon CNP is approved as YUVIWEL^® in the U.S. as a treatment for children with achondroplasia. Ascendis Pharma’s Marketing Authorisation Application for YUVIWEL is under review by the European Medicines Agency, with a decision anticipated in the fourth quarter of 2026.

About TransCon hGH
TransCon hGH (lonapegsomatropin) is a prodrug of somatropin administered once weekly, providing sustained release of active, unmodified somatropin. TransCon hGH is investigational in achondroplasia and is approved as SKYTROFA^® in the U.S., EU, EEA, and elsewhere for the treatment of growth failure in children due to growth hormone deficiency and in the U.S. for the replacement of endogenous growth hormone in adults with growth hormone deficiency.

About Hypoparathyroidism
Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH), the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidney and indirectly on the intestine. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for the majority of cases (70-80%), while other etiologies include autoimmune, idiopathic, and genetic causes, including ADH1.

About Achondroplasia
Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, causing serious muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia vary across different stages of life. Throughout infancy and childhood, observed complications include spinal abnormalities, enlarged brain ventricles, impaired muscle strength and stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; many of these persist or worsen in adulthood. These medical complications can affect physical well-being and quality of life, and may be impacted by a range of individual, clinical, and social factors. Some individuals with achondroplasia require multiple procedures and surgeries to address specific functional or anatomical concerns.

About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ planned oral presentation and posters at ASBMR 2026, (ii) the combined skeletal data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials, including normalization of bone mass and microarchitecture in clinical trial patients treated with TransCon PTH (palopegteriparatide) over a 5-year period, (iii) the unique potential for Ascendis’ highly differentiated TransCon-based therapies to improve patient health and quality of life, (iv) the potential for long-term data to help inform treatment paradigms focused on outcomes that matter most to patients, (v) Ascendis’ plan to share additional results as its programs advance, (vi) Ascendis’ clinical development activities, including the ApproaCH Trial open-label extension and the Phase 2 COACH Trial of navepegritide combined with lonapegsomatropin, (vii) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients and (viii) Ascendis’ use of TransCon to create new and potentially best-in-class therapies to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA^®, YORVIPATH^®, and YUVIWEL^® are trademarks owned by the Ascendis Pharma group. © October 2026 Ascendis Pharma A/S.

Investor Contact:	Media Contact:
Chad Fugere	Melinda Baker
Ascendis Pharma	Ascendis Pharma
+1 (650) 519-7494	+1 (650) 709-8875